logo
logo

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing To Advance The Development Of Novel, Targeted Treatment For Hypertension

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing To Advance The Development Of Novel, Targeted Treatment For Hypertension

06/08/22, 8:00 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgphiladelphia
Money raised
$118 million
Round Type
series b
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, today announced the completion of an oversubscribed and up-sized $118 million Series B financing.

Company Info

Company
Mineralys Therapeutics
Location
philadelphia, pennsylvania, united states
Additional Info
Headquartered in Philadelphia, PA, Mineralys Therapeutics, Inc. is a private, clinical-stage biopharmaceutical company, founded by Catalys Pacific, and is committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. For more information, please visit https://mineralystx.com/.